Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xencor Inc (NQ: XNCR )

26.86 -1.60 (-5.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 396,647
Open 28.31
Bid (Size) 26.85 (20)
Ask (Size) 28.84 (1)
Prev. Close 28.46
Today's Range 26.83 - 28.31
52wk Range 19.36 - 38.20
Shares Outstanding 59,924,016
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
From Xencor, Inc.
Via Business Wire
Xencor Reports Fourth Quarter and Full Year 2022 Financial Results
From Xencor, Inc.
Via Business Wire

Performance

YTD
+3.51%
+3.51%
1 Month
-21.32%
-21.32%
3 Month
+4.47%
+4.47%
6 Month
-0.33%
-0.33%
1 Year
-7.41%
-7.41%

More News

Read More
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
From Xencor, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Collapse In February
Via Benzinga
Why Shares of Zencor Rose This Week
Via The Motley Fool
Xencor's Return On Capital Employed Overview
Via Benzinga
Earnings Scheduled For February 23, 2023
Via Benzinga
Xencor to Present at the SVB Securities Global Biopharma Conference
From Xencor, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
Via Benzinga
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
Via MarketBeat
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
From Xencor, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Xencor, Inc.
Via Business Wire
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
From Xencor, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
Xencor Reports Third Quarter 2022 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
From Xencor, Inc.
Via Business Wire
Earnings Scheduled For November 7, 2022
Via Benzinga
Xencor Earnings Preview
Via Benzinga
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
From Xencor, Inc.
Via Business Wire
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
From Xencor, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Via Benzinga
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.